… axis in the development of CRPC lies in the … CRPC compared to hormone-naïve prostate
cancer (18-21). Recent studies have demonstrated that intra-tumoral androgen levels in CRPC …

… Our study identified five papers that evaluated the prevalence of CRPC in patients with
prostate cancer. Estimates of the proportion of prostate cancer patients who develop CRPC …

… The historic standard treatment for metastatic castration-resistant prostate cancer (CRPC),
docetaxel, provides a median overall survival improvement of roughly 3 months. …

… in prostate cancer and the development of CRPC and promising new agents against CRPC.
… In the progression of prostate cancer to CRPC, prostate cancer survives and resumes its …

… the terms CRPC or castration recurrent prostate cancer were … in the resistant of prostate
cancer cells to testosterone … the Prostate Cancer Working Group (PCWG2) defined CRPC …

… We used two monthly curated databases of patients with castration-resistant prostate
cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era. …

… Background: The availability of new agents for men with CRPC, recognition of new disease
phenotypes, and an evolving regulatory environment have created the need for new CRPC …

… -resistant prostate cancer (CRPC) is a heterogeneous disease with prognoses varying
significantly between patients. In addition, the assessment of treatment response in CRPC …

… The average survival for patients with castration-resistant prostate cancer (CRPC) is 2–3 yr.
… have enhanced our understanding of the biology of CRPC. Biomarkers are considered in the …

… With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa,
… resistant prostate cancer (CRPC), which eventually led to mortality. Due to CRPC being …